Navigation Links
CompanDX Ltd. and Clinical Reference Laboratory, Inc. Sign Multi-Year Deal in Support of Collaborative Gene Signature and Companion Diagnostic Development
Date:2/19/2011

LENEXA, Kan., Feb. 19, 2011 /PRNewswire/ -- CompanDX Ltd., bioinformatics partner for the life sciences industry, and Clinical Reference Laboratory, Inc. (CRL), provider of laboratory testing services in molecular diagnostics and clinical trials, today announced they entered into a multi-year agreement to collaborate in the development and support of biomarker panels and companion diagnostic development for pharmaceutical, biotech and academic clients worldwide. Under the terms of the agreement, CompanDX will continue its trailblazing bioinformatics work on its "Distiller" platform, which includes the development of the first "Time to Event" breast cancer signature supported by CRL's CLIA-certified laboratory services.

The agreement today paves the way for CRL and CompanDX to deliver "discovery to validated test" services to their respective clients.  "CRL has a strong, long-standing reputation for providing state-of-the-art CLIA-certified testing services. In forging this relationship it allows us to reach both upstream and downstream to significantly broadening our reach into the growing market of Molecular Diagnostics, Stratified Clinical Trails and Personalized Medicine," said AD Sutton, CEO, CompanDX.

"Clients are looking for our help to support their clinical development programmes either by reducing the complexity of genomic or proteomic data or by proving innovative MDx tests that will allow them to stratify clinical trials.  CRL brings a level of expertise in the design and delivery of MDx tests that ideally compliments our innovative approach."

CRL's Executive Director of Molecular Diagnostics, Dr. Heather Fehling agrees, "CRL and CompanDX created a powerful team to help meet client's challenges in identifying meaningful biomarker panels and developing novel MDx testing for those panels.  CRL is excited to link its years of CLIA-certified laboratory experience with CompanDX's cutting edge bioinformatics tools to create a unique team offering quality molecular services."

CompanDX's bioinformatics technology will be exhibited at CRL's Booth #630 at the Molecular Medicine Tri-Conference in San Francisco from February 23-25, 2011. CompanDX will also present three posters at the main Tri-Conference, describing novel "Time to Event" breast cancer and "Effect Based" TB tests and an innovative systems biology tool "Therapy Distiller."  In addition, Adam Gouldsworthy, Ph.D., Business Development Manager, CompanDX is presenting a talk, ""Distilling" Personalized Medicine – From Biomarker Discovery to "Time-to-Event Prognostics" at the Early Oncology Partnering Forum in San Francisco on February 21 at 3.26 p.m.

About CompanDX Ltd.

CompanDX is a biomarker discovery and service company that uses its "Distiller" platform to derive small composite biomarker panels from clients genomic and proteomic data in support of stratified clinical trials.  Privately-held, CompanDX is based in Nottingham, UK. Investors in the company include Lachesis and Mobius Funds. Additional information is available at www.compandx.com

About Clinical Reference Laboratory, Inc.

Established in 1979, CRL is a privately held reference laboratory in Lenexa, Kansas offering leading-edge testing services in the areas of Clinical Trials, Corporate Wellness Programs, Genomics, Insurance, Molecular Diagnostics, BioAnalytics and Toxicology. CRL is one of the largest single-site laboratories in the US and analyzes over 100 million tests annually.  In addition, CRL has a satellite laboratory near Cambridge, UK.  Additional information is available at www.crlcorp.com.


'/>"/>
SOURCE Clinical Reference Laboratory, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)... -- Global Immunology Market to 2022 - Large ... growth Summary Immune-mediated inflammatory diseases are ... affect 5–7% of western populations. Although they are ... key patient demographics, they are pathophysiologically linked, being ... inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology:
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... 05, 2016 , ... Pivot Point Consulting, a leading national ... & Services for HIT Implementation Support & Staffing report with an outstanding score ... by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Colorize ... from on one drop zone to the next using Colorize's dynamic moving camera. Colorize ... project. This package includes a 3D slideshow environment with 1 to 5 focus points ...
(Date:2/5/2016)... ... 05, 2016 , ... Calls Blacklist has just been updated by mobile app ... the developer has fixed known bugs within the app. Calls Blacklist allows its users ... not consuming any of their device’s battery power or memory. It provides a powerful ...
Breaking Medicine News(10 mins):